Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1994 2
1995 2
1996 1
1997 1
2002 1
2015 1
2016 2
2017 3
2018 3
2019 3
2020 3
2021 7
2022 3
2023 3
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
The Danish National Multiple Myeloma Registry.
Gimsing P, Holmström MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, Plesner T, Pedersen PT, Frederiksen M, Frølund U, Helleberg C, Vangsted A, de Nully Brown P, Abildgaard N. Gimsing P, et al. Among authors: helleberg c. Clin Epidemiol. 2016 Oct 25;8:583-587. doi: 10.2147/CLEP.S99463. eCollection 2016. Clin Epidemiol. 2016. PMID: 27822103 Free PMC article. Review.
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
Lund T, Gundesen MT, Juul Vangsted A, Helleberg C, Haukås E, Silkjær T, Asmussen JT, Manuela Teodorescu E, Amdi Jensen B, Schmidt Slørdahl T, Nahi H, Waage A, Abildgaard N, Schjesvold F; Nordic Myeloma Study Group. Lund T, et al. Among authors: helleberg c. Blood Cancer J. 2024 Apr 15;14(1):65. doi: 10.1038/s41408-024-01046-2. Blood Cancer J. 2024. PMID: 38622134 Free PMC article. No abstract available.
Potential value of pre-planned imaging of bone disease in multiple myeloma.
Gundesen MT, Asmussen JT, Schjesvold F, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Teodorescu EM, Jensen BA, Slørdahl TS, Nahi H, Waage A, Abildgaard N, Lund T; Nordic Myeloma Study Group. Gundesen MT, et al. Among authors: helleberg c. Blood Cancer J. 2023 Jul 7;13(1):105. doi: 10.1038/s41408-023-00880-0. Blood Cancer J. 2023. PMID: 37419876 Free PMC article. No abstract available.
The real-world outcomes of multiple myeloma patients treated with daratumumab.
Szabo AG, Klausen TW, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Gjerdrum LMR, Bønløkke ST, Nielsen K, Kjeldsen E, Iversen KF, Teodorescu EM, Dokhi M, Kurt E, Strandholdt C, Andersen MK, Vangsted AJ. Szabo AG, et al. Among authors: helleberg c. PLoS One. 2021 Oct 13;16(10):e0258487. doi: 10.1371/journal.pone.0258487. eCollection 2021. PLoS One. 2021. PMID: 34644367 Free PMC article.
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.
Szabo AG, Thorsen J, Iversen KF, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Gjerdrum LMR, Bønløkke ST, Nielsen K, Kjeldsen E, Teodorescu EM, Dokhi M, Kurt E, Strandholdt CN, Andersen MK, Vangsted AJ. Szabo AG, et al. Among authors: helleberg c. Am J Hematol. 2022 Mar 1;97(3):E117-E120. doi: 10.1002/ajh.26449. Epub 2021 Dec 29. Am J Hematol. 2022. PMID: 34967035 Free article. No abstract available.
Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015.
Olesen TB, Andersen IT, Ording AG, Ehrenstein V, Seesaghur A, Helleberg C, Silkjær T, Hernandez RK, Niepel D, Abildgaard N. Olesen TB, et al. Among authors: helleberg c. Support Care Cancer. 2021 Aug;29(8):4501-4511. doi: 10.1007/s00520-020-05934-8. Epub 2021 Jan 18. Support Care Cancer. 2021. PMID: 33458807
33 results